Page 2 - Nasdaq Cyad News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage...

Celyad Oncology (NASDAQ:CYAD – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $2.25 price target on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 7.66% from the company’s […]

MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext...

MONT-SAINT-GUIBERT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“Celyad” or the “Company”), a...

Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium January 18, 2021 01:00 ET | Source: Celyad Oncology SE Celyad Oncology SE Mont-Saint-Guibert, BELGIUM Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively Tumor burden decrease observed in eight of 15 refractory unresectable mCRC patients, including six of nine patients at the highest dose level of 1x10 9 cells per infusion Emergence of new T...